Subdermal Contraceptive Implants Market To Reach $1.74 Billion By 2030

Subdermal Contraceptive Implants Market Growth & Trends

The global subdermal contraceptive implants market size is estimated to reach USD 1.74 billion by 2030, registering to grow at a CAGR of 7.61% from 2025 to 2030 according to a new report by Grand View Research, Inc. Introduction of several modern contraceptives in the market, growing awareness about various birth control methods, and high per capita income are some of the key factors driving the market for subdermal implants for birth control.

According to the Guttmacher Institute, in 2014, approximately 20 million women needed publicly funded contraceptive services. According to CDC, in 2017, nearly 46.9 million women in the U.S. were using at least one method of contraception. Subdermal implant is a long-term birth control option for women. Subdermal implants for contraception are in the form of polymer capsules or rods placed under the skin. The progestational hormone is released at a slow and stable rate, providing effective contraception for 1-5 years.

Publicly funded family planning services help women avoid or plan pregnancies. In 2012, the South Carolina Department of Health and Human Services (SCDHHS) revised the cost associated with Medicaid payment policy for immediate postpartum insertion of Long-Acting Reversible Contraception (LARC). Under this new reimbursement policy, providers are allowed to bill for the insertion procedure and the cost of an IUD or an implant, in addition to the Diagnosis Related Group (DRG) by using J-codes with a family planning modifier.

Implants are the most widely used contraceptive methods by women in sub-Saharan Africa owing to public-private partnerships between manufacturers, donors, governments, and international agencies, which helps lower commodity cost and increase product availability. Contraceptive usage has increased in South Africa, Malawi, and Rwanda. According to PLOS.org, in Malawi, the use of the Long-acting Reversible Contraception (LARC) method reached 10.21% in urban areas in 2016 and 9.66% in rural areas. In 2012, an initiative called Family Planning 2020 (FP2020) was launched to give 120 million women access to modern contraceptive methods by 2020.

 Request a free sample copy or view report summary: Subdermal Contraceptive Implants Market Report

Subdermal Contraceptive Implants Market Report Highlights

• Etonogestrel implants dominated the market and accounted for a share of 64.73% in 2024. The driving factors are rising unintended pregnancies and unsafe abortions.

• Hospital dominated the market and accounted for a share of 54.37% in 2024. Hospitals provide a comprehensive environment for patients, offering a wide range of services including tests, consultations, and procedures, which drive segment growth.

• North America subdermal contraceptive implants market dominated the market with a market share of 64.91% in 2024.

Subdermal Contraceptive Implants Market Segmentation

Grand View Research has segmented the global subdermal contraceptive implants market based on product, distribution channel, and region:

Subdermal Contraceptive Implants Product Outlook (Revenue, USD Million, 2018 - 2030)

• Etonogestrel Implant

• Levonorgestrel Implant

Subdermal Contraceptive Implants Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital

• Gynecology Clinics

• Community Health Care Centers

• Others

Subdermal Contraceptive Implants Regional Outlook (Revenue, USD Million, 2018-2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Subdermal Contraceptive Implants Market

• Merck & Co., Inc.

• Shanghai Dahua Pharmaceutical Co., Ltd.

• Bayer AG

• Baxter

• BD

• Gerresheimer AG

• Pfizer, Inc.

• Novartis AG

• SCHOTT

• Lilly